» Articles » PMID: 18550029

MCF-7aro/ERE, a Novel Cell Line for Rapid Screening of Aromatase Inhibitors, ERalpha Ligands and ERRalpha Ligands

Overview
Date 2008 Jun 14
PMID 18550029
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously generated a breast cancer cell line, MCF-7aro, which over-expresses aromatase and is also ER positive. Recently, this MCF-7aro cell line was stably transfected with a promoter reporter plasmid, pGL3-Luc, containing three repeats of estrogen responsive element (ERE). Experiments using MCF-7aro/ERE have demonstrated that it is a novel, non-radioactive screening system for aromatase inhibitors (AIs), ERalpha ligands and ERRalpha ligands. The screening is carried out in a 96-well plate format. To evaluate this system, the cells were cultured overnight in charcoal-dextran stripped FBS medium supplemented with 0.1 nM testosterone or 17beta-estradiol, and various concentrations of antiestrogens or AIs. We found that the luciferase activity was induced when the cells were cultured either in the presence of testosterone or 17beta-estradiol. Furthermore, a 50% decrease in luciferase activity could be achieved when the cells were cultured in the presence of testosterone together with letrozole, anastrozole, tamoxifen or fulvestrant (concentrations being 75 nM, 290 nM, 100 nM, and 5 nM, respectively), compared to the testosterone-only cultured cells. Using this assay system, we confirmed that 3(2'-chlorophenyl)-7-methoxy-4-phenylcoumarin is an agonist of ER. Furthermore, genestein has been shown to be a ligand of ERRalpha because its binding could be blocked by an ERRalpha inverse agonist, XCT790. These results indicate that MCF-7aro/ERE is a novel cell line for rapid screening of AIs, ERalpha ligands and ERRalpha ligands.

Citing Articles

Evaluation of new alternative methods for the identification of estrogenic, androgenic and steroidogenic effects: a comparative in vitro/in silico study.

Najjar A, Wilm A, Meinhardt J, Mueller N, Boettcher M, Ebmeyer J Arch Toxicol. 2023; 98(1):251-266.

PMID: 37819454 PMC: 10761396. DOI: 10.1007/s00204-023-03616-y.


Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical Trials.

Wang X, Chan Y, Wong K, Yoshitake R, Sadava D, Synold T Cancers (Basel). 2023; 15(3).

PMID: 36765659 PMC: 9913787. DOI: 10.3390/cancers15030701.


Exploring the Biological Activity and Mechanism of Xenoestrogens and Phytoestrogens in Cancers: Emerging Methods and Concepts.

Wang X, Ha D, Yoshitake R, Chan Y, Sadava D, Chen S Int J Mol Sci. 2021; 22(16).

PMID: 34445499 PMC: 8395949. DOI: 10.3390/ijms22168798.


Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells.

Wang Y, Tzeng Y, Chang G, Wang X, Chen S Endocr Relat Cancer. 2020; 27(12):671-683.

PMID: 33112819 PMC: 7665895. DOI: 10.1530/ERC-20-0258.


Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA.

Sun P, Mao X, Gao M, Huang M, Chen L, Ruan G Cancer Manag Res. 2018; 10:2521-2535.

PMID: 30127640 PMC: 6089116. DOI: 10.2147/CMAR.S168043.


References
1.
Willy P, Murray I, Qian J, Busch B, Stevens Jr W, Martin R . Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc Natl Acad Sci U S A. 2004; 101(24):8912-7. PMC: 428446. DOI: 10.1073/pnas.0401420101. View

2.
Dauvois S, Danielian P, White R, Parker M . Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A. 1992; 89(9):4037-41. PMC: 525627. DOI: 10.1073/pnas.89.9.4037. View

3.
Suetsugi M, Su L, Karlsberg K, Yuan Y, Chen S . Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003; 1(13):981-91. View

4.
Ariazi E, Ariazi J, Cordera F, Jordan V . Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006; 6(3):181-202. View

5.
Zhou D, Pompon D, Chen S . Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 1990; 50(21):6949-54. View